(Reuters) – British drugmaker GSK announced its intention to sell up to 240 million shares in Haleon on Thursday, which represents 2.5% of the consumer healthcare group’s issued share capital.
GSK, which is the second largest shareholder of London-listed Haleon, said it will sell the stake via a placing of ordinary shares. The offer price will be determined through an accelerated bookbuild offering process, which will commence immediately.
Haleon’s shares closed marginally up 0.9% at 342.85 pence on May 11.
(Reporting by Anchal Rana in Bengaluru; Editing by Krishna Chandra Eluri)
